

# Esophageal Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/E76B90437CAEN.html>

Date: March 2020

Pages: 1342

Price: US\$ 2,000.00 (Single User License)

ID: E76B90437CAEN

## Abstracts

Esophageal Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H1 2020, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and

Unknown stages are 1, 11, 69, 81, 5, 34, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Esophageal Cancer - Overview

Esophageal Cancer - Therapeutics Development

Esophageal Cancer - Therapeutics Assessment

Esophageal Cancer - Companies Involved in Therapeutics Development

Esophageal Cancer - Drug Profiles

Esophageal Cancer - Dormant Projects

Esophageal Cancer - Discontinued Products

Esophageal Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Esophageal Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Esophageal Cancer - Pipeline by AbbVie Inc, H1 2020  
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020  
Esophageal Cancer - Pipeline by ADC Therapeutics SA, H1 2020  
Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2020  
Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020  
Esophageal Cancer - Pipeline by Affimed GmbH, H1 2020  
Esophageal Cancer - Pipeline by Agios Pharmaceuticals Inc, H1 2020  
Esophageal Cancer - Pipeline by Akeso Biopharma Inc, H1 2020  
Esophageal Cancer - Pipeline by Alphamab Oncology, H1 2020  
Esophageal Cancer - Pipeline by Ambrx Inc, H1 2020  
Esophageal Cancer - Pipeline by amcure GmbH, H1 2020  
Esophageal Cancer - Pipeline by AMI Onco Theranostics LLC, H1 2020  
Esophageal Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020  
Esophageal Cancer - Dormant Projects, H1 2020  
Esophageal Cancer - Discontinued Products, H1 2020  
Esophageal Cancer - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Esophageal Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
Adaptimmune Therapeutics Plc  
ADC Therapeutics SA  
Advanced Accelerator Applications SA  
Advenchen Laboratories LLC  
Affimed GmbH  
Agiros Pharmaceuticals Inc  
Akeso Biopharma Inc  
Alphamab Oncology  
Ambrx Inc  
amcure GmbH  
AMI Onco Theranostics LLC  
Anhui Anke Biotechnology (Group) Co Ltd  
Anhui Kedgene Biotechnology Co Ltd  
Apexigen Inc  
Apollomics Inc  
Aprea Therapeutics AB  
Ascenta Therapeutics Inc  
Ascentage Pharma Group International  
Astellas Pharma Inc  
AstraZeneca Plc

AVEO Oncology Inc  
Bayer AG  
BeiGene Ltd  
Bicycle Therapeutics Plc  
BioMed Valley Discoveries Inc  
Biostage Inc  
BioStar Pharmaceuticals Inc  
Boehringer Ingelheim International GmbH  
Bristol-Myers Squibb Co  
Cantargia AB  
Celldex Therapeutics Inc  
Cellular Biomedicine Group Inc  
Chi Cheung (Shanghai) Biomedical Co Ltd  
Chugai Pharmaceutical Co Ltd  
Coherent Biopharma  
Cotinga Pharmaceuticals Inc  
CStone Pharmaceuticals Co Ltd  
Curegenix Inc  
Cyclacel Pharmaceuticals Inc  
Cytlimic Inc  
CytomX Therapeutics Inc  
DAE HWA Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
Delta-Fly Pharma Inc  
Dragonboat Biopharmaceutical (Shanghai)Co Ltd  
Eisai Co Ltd  
Eli Lilly and Co  
Evelo Biosciences Inc  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Genmab AS  
GlaxoSmithKline Plc  
GLG Pharma SA  
GlycoNex Inc  
Glycotope GmbH  
Gossamer Bio Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
Guangzhou Anjie Biomedical Technology Co Ltd  
Guangzhou Saliai Stemcell Science and Technology Co Ltd

Hanmi Pharmaceuticals Co Ltd  
Harbin Gloria Pharmaceuticals Co Ltd  
HEC Pharm Co Ltd  
Hualan Biological Engineering Inc  
Hutchison MediPharma Ltd  
Idera Pharmaceuticals Inc  
ImmuneSensor Therapeutics Inc  
Immunocore Ltd  
Immunomedics Inc  
ImmunoRestoration LLC  
Immvisa Co Ltd  
Incyte Corp  
Innovent Biologics Inc  
Inovio Pharmaceuticals Inc  
Ipsen SA  
Jacobio Pharmaceuticals Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
Kitov Pharma Ltd  
Kymab Ltd  
Leap Therapeutics Inc  
LEXEO Therapeutics LLC  
LifT BioSciences Ltd  
MaxiVAX SA  
Medical Guidance Systems LLC  
Merck & Co Inc  
Merck KGaA  
Mereo Biopharma Group Plc  
Moderna Inc  
Modra Pharmaceuticals BV  
Molecular Templates Inc  
New B Innovation Ltd  
NGM Biopharmaceuticals Inc  
Novartis AG  
Novita Pharmaceuticals Inc  
OBI Pharma Inc  
Omeros Corp  
Omnitura Therapeutics Inc  
Oncology Venture A/S



Oncolys BioPharma Inc  
Onconova Therapeutics Inc  
Ono Pharmaceutical Co Ltd  
Peptron Inc  
Pfizer Inc  
Pieris Pharmaceuticals Inc  
Prescient Therapeutics Ltd  
Puma Biotechnology Inc  
Rafael Pharmaceuticals Inc  
Rakuten Medical Inc  
RAPT Therapeutics Inc  
RaQualia Pharma Inc  
Replimune Ltd  
Revolution Medicines Inc  
Rhizen Pharmaceuticals SA  
Scancell Holdings Plc  
Seattle Genetics Inc  
Shanghai Haihe Biopharma Co Ltd  
Shanghai Henlius Biotech Inc  
Shanghai Junshi Bioscience Co Ltd  
Shanghai Keqi Pharmaceutical Technology Co Ltd  
Shenyang Dongxing Pharmaceutical Co Ltd  
Shenzhen BinDeBio Ltd  
Shenzhen Hornetcorn Bio-technology Company Ltd  
Shenzhen NeoCura Biotechnology Corp  
Shionogi & Co Ltd  
Sino Biopharmaceutical Ltd  
Sinocelltech Ltd  
Soricimed Biopharma Inc  
Sorrento Therapeutics Inc  
Starpharma Holdings Ltd  
Steba Biotech SA  
Stemirna Therapeutics Inc  
Supratek Pharma Inc  
Suzhou Sinovent Pharmaceuticals Co Ltd  
Suzhou Stainwei Biotech Inc  
Taiho Pharmaceutical Co Ltd  
Takara Bio Inc  
Takeda Pharmaceutical Co Ltd

Telix Pharmaceuticals Ltd  
Tessa Therapeutics Pte Ltd  
Themis Bioscience GmbH  
TOT Biopharm Co Ltd  
Transgene Biotek Ltd  
Transgene SA  
Turnstone Biologics Inc  
Tyg Oncology Ltd  
Veana Therapeutics LLC  
Viral Gene Inc  
Xiangxue Life Sciences  
XuanZhu Pharma Co Ltd  
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd  
Zymeworks Inc

## I would like to order

Product name: Esophageal Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/E76B90437CAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E76B90437CAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970